RedHill sees positive results for anti-MAP Crohn’s drug
Drug could be “paradigm shift” in $10 billion industry
Read More
Author: George Underwood
Takeda signs antibody therapy deal with HiFiBiO
Companies will research multiple targets in gastrointestinal diseases, cancers and other disorders
Read More
Keytruda-chemotherapy combination gets CHMP nod
Drug also recommended for approval in head and neck squamous cell carcinoma
Read More
Q2 results roundup – 27 July
The latest financial results from Amgen, Astellas, AZ, BMS and Celgene
Read More
Brexit ambition is ‘fine’ but execution is key, says Brexit Health Alliance
“There is always a danger that health issues are not kept to the fore” in negotiations, says Niall Dickson
Read More- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
- CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
- FDA approves new high dose Spinraza regimen for SMA
